8.3 Sex hormones and hormone antagonists in malignant disease

Homepage

Search the NeLM

Medicines A-Z

Find key information about medicines by name (prototype)

Browse by Categories:

Browse by NeLM area:

BNF Category

343 library items in 8.3 Sex hormones and hormone antagonists in malignant disease

Filter results by:

Date Published

NeLM Area

News
Other Library Updates
Health In Focus
Evidence
Medicines A-Z
Communities
Formularies

Results filtered by:

Category

8: Malignant disease and immunosuppression (remove) , 8.3 Sex hormones and hormone antagonists in malign (remove)

Sort by: Display summary:

Results 1 - 10 of 343

Result page:
Previous
|
1
2
3
4
5
6
7
8
9
10
11
|
Next

1.

Randomised Phase II study of everolimus in combination with tamoxifen in metastatic breast cancer

Source: Journal of Clinical Oncology,
Date published: 09/05/2012

Category:

8.1.5 Other antineoplastic drugs | 8.3.4 Hormone antagonists | Cancer: breast

NeLM Area:

News

Link (abstract)
2.

CYP2D6 genotype does not predict response to tamoxifen

Source: J Natl Cancer Inst ,
Date published: 19/03/2012

Category:

8.3.4 Hormone antagonists | Cancer: breast

NeLM Area:

News

Study 1 (abstract)

Study 2 (abstract)

Editorial (extract)
3.

Marketing authorisation application withdrawn for Megestrol Alkermes™ (megestrol)

Source: EMA,
Date published: 14/03/2012

Category:

8.3.2 Progestogens | European Agency for the Evaluation of Medicinal Products (EMEA) | HIV Infection/AIDS | Oncology | Product Discontinuation

NeLM Area:

News

Link
4.

Cohort study of somatostatin-based radiopeptide therapy with single vs. combination radioisotopes for metastatic neuroendocrine tumours

Source: Journal of Clinical Oncology,
Date published: 06/03/2012

Category:

8.3.4 Hormone antagonists | Cancer: other

NeLM Area:

News

Abstract
5.

Adjuvant tamoxifen reduces subsequent breast cancer in oestrogen receptor–positive ductal carcinoma in situ

Source: Journal of Clinical Oncology,
Date published: 06/03/2012

Category:

8.3.4 Hormone antagonists | Cancer: breast

NeLM Area:

News

Abstract

Editorial
6.

Fulvestrant combination with anastrazole shows no benefit as first-line therapy for patients with receptor-positive postmenopausal breast cancer – results from the FACT trial

Source: Journal of Clinical Oncology,
Date published: 29/02/2012

Category:

8.3.4 Hormone antagonists | Cancer: breast

NeLM Area:

News

Abstract
7.

AWMSG recommends abiraterone (Zytiga®) for prostate cancer

Source: All Wales Medicines Strategy Group (AWMSG),
Date published: 20/02/2012

Category:

8.3.4 Hormone antagonists | All Wales Medicines Strategy Group (AWMSG) | Cancer: prostate | Drug reviews

NeLM Area:

Evidence > Drug Specific Reviews

Link
8.

AWMSG recommends abiraterone (Zytiga®) for prostate cancer

Source: All Wales Medicines Strategy Group (AWMSG),
Date published: 20/02/2012

Category:

8.3.4 Hormone antagonists | All Wales Medicines Strategy Group (AWMSG) | Cancer: prostate | Drug reviews

NeLM Area:

Evidence > Drug Specific Reviews

Link
9.

Outcomes of aromatase inhibitor therapy switching in patients experiencing treatment emergent adverse effects

Source: JCO,
Date published: 15/02/2012

Category:

8.3.3 Androgens | Adverse Drug Reactions | Cancer: breast

NeLM Area:

News

Abstract
10.

Subanalysis of the MAP.3 study finds exemestane for primary prevention of breast cancer worsens age-related BMD decreases

Source: Lancet Oncology,
Date published: 07/02/2012

Category:

8.3.4 Hormone antagonists | Adverse Drug Reactions | Cancer: breast

NeLM Area:

News

Link (abstract)

Comment

MAP.3 study results (NeLM report)

Results 1 - 10 of 343

Result page:
Previous
|
1
2
3
4
5
6
7
8
9
10
11
|
Next